Posted by Michael Wonder on 21 Feb 2025
EMA validates indication extension application for Aspaveli for treatment of C3G and primary IC-MPGN
20 February 2025 - Sobi and Apellis Pharmaceuticals today announced the EMA has validated an indication extension application for Aspaveli (pegcetacoplan) for the treatment of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, which are rare, chronic kidney diseases with no approved treatments.
The submission includes positive data from the Phase 3 VALIANT study.
